{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-043828","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.032086+00:00","generated_at":"2026-05-24T06:50:37.293910+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Artiva reports 2024 net loss of $65.4M; cash $185.4M; autoimmune data expected H1 2025","bullets":["Net loss of $65.4M in 2024 vs net income of $28.7M in 2023; no collaboration revenue vs $32.9M prior year.","Cash, cash equivalents and investments $185.4M at Dec 31, 2024, expected to fund operations through end of 2026.","Initial data from AlloNK (AB-101) in autoimmune indications (SLE/LN, RA) expected in H1 2025.","Appointed Dan Baker to Board and added SVP-level leadership in Regulatory, Clinical Ops, and Biometrics.","Updated Phase 1/2 NHL trial data for AlloNK + rituximab showing durability to be presented at 2025 medical conference."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-043828","json":"https://secwatch.observer/filing/0000950170-25-043828.json","markdown":"https://secwatch.observer/filing/0000950170-25-043828.md","text":"https://secwatch.observer/filing/0000950170-25-043828.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000095017025043828/0000950170-25-043828-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000095017025043828/artv-20250324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:50:37.293910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}